ECM
HAE icon

ExodusPoint Capital Management’s Haemonetics HAE Stock Holding History

ExodusPoint Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,000
Closed -$1.75M – 2115
2020
Q3 		$1.75M Buy
+20,000
New +$1.75M 0.03% 447

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ExodusPoint Capital Management's HAE Position: Q2 2026 in Review

ExodusPoint Capital Management sold out of Haemonetics (HAE) in Q2 2026, closing a stake of 47,750 shares — an estimated $2.69M sold.

ExodusPoint Capital Management first reported a position in HAE in Q4 2019 and held it in 17 quarters. The position peaked at $15.2M in Q3 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • ExodusPoint Capital Management reported no remaining Haemonetics position as of Q2 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 47,750 Haemonetics shares in Q2 2026, an estimated $2.69M.
  • ExodusPoint Capital Management first reported a position in Haemonetics in Q4 2019 and held it in 17 quarters.
  • ExodusPoint Capital Management's Haemonetics position peaked at $15.2M in Q3 2025.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.